Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 7/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.35 |
| ▸ | CNR2 | P34972 | 8/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11933180 | 0.97 | FEN1 (0.37) | FEN1ALOX5APCNR2CNR1SCN9A | |
| SCHEMBL11933328 | 0.97 | FEN1 (0.37) | FEN1ALOX5APCNR2CNR1SCN9A | |
| SCHEMBL14922516 | 0.95 | FEN1 (0.38) | FEN1ALOX5APCNR2CNR1SCN9A | |
| SCHEMBL12196592 | 0.94 | SCN9A (0.34) | FEN1ALOX5APSCN9A | |
| SCHEMBL14922551 | 0.93 | FEN1 (0.37) | FEN1ALOX5APCNR2CNR1SCN9A | |
| SCHEMBL10302327 | 0.93 | ALOX5AP (0.35) | FEN1ALOX5APCNR2CNR1SCN9A | |
| SCHEMBL12196501 | 0.93 | ALOX5AP (0.35) | FEN1ALOX5APCNR2CNR1SCN9A | |
| SCHEMBL2509012 | 0.92 | FEN1 (0.36) | FEN1ALOX5APCNR2CNR1SCN9A | |
| SCHEMBL12196873 | 0.92 | CNR2 (0.36) | FEN1ALOX5APCNR2CNR1SCN9A | |
| SCHEMBL15381768 | 0.92 | FEN1 (0.40) | FEN1ALOX5APCNR2CNR1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | FEN1 3903/4885ALOX5AP 1073/4885CNR2 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.